BMS’ Opdivo (nivolumab) Receives CHMP Recommendation for Approval of its Four-Week Dosing Schedule

 BMS’ Opdivo (nivolumab) Receives CHMP Recommendation for Approval of its Four-Week Dosing Schedule

Bristol Myer Reports Results of Orencia (abatacept) in P-IV Early AMPLE Study for Moderate-to-Severe Rheumatoid Arthritis #EULAR2019

Shots:

  • The EMA’s CHMP has recommended approval of Opdivo flat dosing schedule 240 mg infused over 30min. (q2w) or 480mg infused over 60min. (q4w) for the adjuvant treatment of adult patients with melanoma involvement of lymph nodes or metastatic disease who have undergone complete resection
  • The positive CHMP opinion for two and four-week dosing of Opdivo supports BMS’ commitment to offer flexible dosing options for patients, caregivers and healthcare providers
  • Opdivo is a PD-1 immune check inhibitor harnessing the body’s own immune system to restore anti-tumor immune response and is an approved therapy in 65+ countries including the US, EU, Japan & China

Click here to­ read full press release/ article | Ref: BMS | Image: Pharmaceutical Technology

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post